CHEMOTHERAPY
Online ISSN : 1884-5894
Print ISSN : 0009-3165
ISSN-L : 0009-3165
Search
Advanced search
OR
Browse
Search
Volume 42, Issue Supplement4
Displaying 101-120 of 120 articles from this issue
Show all abstracts
  • Clinical study on biapenem in complicated urinary tract infections
    Aiichiro Masuda, Kazuo Arihara, Toshiya Ishida, Yoji Katsuoka, Hidechi ...
    1994 Volume 42 Issue Supplement4 Pages 795-799
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_795
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We evaluated clinical efficacy and safety of biapenem (BIPM), a new carbapenem antibiotic, was administered to 22 patients with complicated urinary tract infections, at a dose 150mg or 300mg twice daily.
    Twenty of 22 patients were evaluated according to the UTI committee's criteria. The clinical efficacy was excellent in 5, moderate in 8 and poor in 7.
    No adverse reaction was observed. Abnormal laboratory findings were found in 2 cases of slight hepatic dysfunction and 1 of slight elevation of basocyte and hepatic dysfunction.
    View full abstract
    Download PDF (643K)
  • Clinical evaluation of biapenem in chronic complicated urinary tract infection
    Kiyoshi Koshida, Haruo Hisazumi
    1994 Volume 42 Issue Supplement4 Pages 800-802
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_800
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We evaluated the clinical efficacy and safety of biapenem (BIPM), a new injectable carbapenem antibiotic, in 5 patients with chronic complicated urinary tract infection. The overall clinical efficacy in 4 cases evaluated by the Japanese UTI Committee criteria was excellent in 3 and moderate in 1 case. The clinical efficacy evaluated by the physicians was excellent in 3 and good in 2 cases.
    Bacteriologically, all strains (4 strains) were eradicated.
    No subjective side effects were observed, but laboratory findings revealed mild elevation of GOT and GPT in one case.
    View full abstract
    Download PDF (337K)
  • Clinical experience with biapenem in complicated urinary tract infection
    Shutaro Mizutani, Kazuo Nishimura, Kazuhiro Yoshimura, Susumu Miyoshi, ...
    1994 Volume 42 Issue Supplement4 Pages 803-808
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_803
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Twenty patients with complicated urinary tract infections, two of them were dropped out of effect evaluation, were given biapenem (BIPM) at a daily dose of 0.6g (in 15 cases) or 0.9g (in 3 cases) by intravenous drip infusion for five days, and the following results were obtained. Clinical results were excellent in 4 cases, moderate in 10 and poor in 4. The overall clinical efficacy rate was 78%. As to the bacteriological response, 37 strains of total 40 were eliminated. Nine new organisms appeared after treatment. No extraordinary values of the clinical laboratory findings were observed in 20 patients treated by BIPM, except for two cases who showed eosinophilia and elevation of GPT and Al-P.
    View full abstract
    Download PDF (723K)
  • Biapenem in complicated urinary tract infections
    Hirofumi Chokyu, Masuo Yamashita, Soichi Arakawa, Sadao Kamidono, Tate ...
    1994 Volume 42 Issue Supplement4 Pages 809-813
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_809
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Biapenem (BIPM), a new carbapenem antibiotics, was administered to 21 patients with complicated urinary tract infections at a daily dose of 0.3 or 0.6 or 0.9g for 5 days.
    Clinical efficacy as evaluated by the criteria of the Japanese UTI Committee was excellent in 4, moderate in 11, poor in 1 patients, an efficacy rate of 94%.
    Bacteriological response showed elimination of 25 of 26 strains isolated from patients.
    No adverse reactions were observed clinically, but in laboratory findings elevations of liver enzymes were noted in 2 cases.
    View full abstract
    Download PDF (589K)
  • Biapenem in urinary tract infections
    Kenzo Uema, Susumu Kagawa, Makoto Yuasa
    1994 Volume 42 Issue Supplement4 Pages 814-819
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_814
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Biapenem (BIPM) was administered to 14 patients with urinary tract infections (UTI) and 2 patients with acute uncomplicated pyelonephritis and one patient with acute prostatitis at a daily dosage of 600mg b.i.d. for 3-5 days, and its clinical efficacy and safety were evaluated. The following results were observed:
    1) Clinical efficacy was evaluated according of the criteria of the Japanese UTI Committee. The overall efficacy rate was 70% in the 10 patients with chronic complicated UTI.
    2) Bacteriologically, 18 (90%) of 20 strains were eradicated in chronic complicated UTI.
    3) As for side effects, eruption occurred in one patient. Abnormal laboratory findings were transient elevation of GOT, GPT, γ-GTP, ALP, LAP and LDH in one patient.
    From the above results, we consider that BIPM is a useful and safe antibiotic for UTI.
    View full abstract
    Download PDF (605K)
  • Biapenem in complicated urinary tract
    Tetsuro Matsumoto, Shuta Kubo, Masashi Haraoka, Koichi Takahashi, Masa ...
    1994 Volume 42 Issue Supplement4 Pages 820-825
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_820
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Clinical effect and safety of biapenem (BIPM), a new injectable carbapenem antibiotic, was evaluated on 17 patients with complicated urinary tract infection.BIPM was administered by intravenous drip infusion at a dose of 300-450mg twice daily for 5days.
    In 14 cases which were evaluable by the criteria of the Japanese UTI committee, excellent results was observed in 8, moderate in 6 patients, so the effectiveness rate being 100%. Bacteriologically, all 24 strains were eradicated. We noted no adverse reactions or abnormalities of laboratory findings.
    View full abstract
    Download PDF (739K)
  • Clinical study of biapenem in the surgical field
    Yasuo Sawada, Hisashi Ookubo, Tsuyoshi Takahashi, Ikuo Hashimoto
    1994 Volume 42 Issue Supplement4 Pages 826-830
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_826
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We performed clinical and laboratory studies on biapenem (BIPM), in surgical infections. Ten patients received BIPM, the diagnoses was peritonitis 3, panperitonitis due to perforation of the gastric ulcer 1, pelvic peritonitis 1, suppurative cholangitis 1, cholecystitis 2, suppurative mastitis 1 and pyothorax 1.
    The clinical efficacy of BIPM was excellent in 6 cases and good in 4 cases of the 10 cases, the overall efficacy rate being 100%.
    Bacteriological efficacy was investigated in 5 cases: 4 were eradicated and 1 was decreased.
    No side effects were observed, but the abnormal laboratory finding of slight elevations of GOT, GPT and ALP was noted in only 1 case.
    View full abstract
    Download PDF (672K)
  • Clinical study of biapenem in the abdominal surgical field
    Shinya Kusachi, Yoshinobu Sumiyama, Kunihiko Kawai, Minoru Kurita, Yoi ...
    1994 Volume 42 Issue Supplement4 Pages 831-834
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_831
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Biapenem (BIPM) was administered to 10 patients with abdominal surgery.
    Clinical response was excellent in 9 cases and good in 1 case, and the overall clinical efficacy rate was 100%. Bacteriologically, 7 of 10 patients were eradicated, 1 was partially eradicated and 1 was persisted.
    No side effect was observed, but as for abnormal laboratory findings, monocytosis in 1 case and LAP in 1 case increased transiently.
    We therefore consider that BIPM is a safe and useful antibiotic in infectious diseases in surgical field.
    View full abstract
    Download PDF (555K)
  • Clinical study of biapenem in severe surgical infections
    Yoshimi Osakabe, Yoshiki Takahashi
    1994 Volume 42 Issue Supplement4 Pages 835-837
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_835
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We evaluated the clinical efficacy and safety of biapenem (BIPM) in severe surgical infections.
    BIPM was administered to 2 cases with septicemia, 1 case with secondary infection of scald combined with septicemia and 1 case with wound infection. All cases have underlying diseases, which were scald (III°, 15%), traumatic pancreatitis, chronic renal insufficiency, retroperitoneal tumor, acute myelogenous leukemia. BIPM was given by intravenous injection at a dose of 300mg three times a day for 6-8 days.
    The clinical effect was excellent in 1, good in 1, fair in 1, unknown in 1. Neither side effects nor laboratry findeings were observed.
    View full abstract
    Download PDF (521K)
  • Basic and clinical studies of biapenem in the surgical field
    Shigeo Ono, Toyoharu Tanaka, Yoshihumi Takenaka, Keiiti Yoshino
    1994 Volume 42 Issue Supplement4 Pages 838-842
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_838
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A new carbapenem antibiotic biapenem (BIPM) was investigated in terms of the serum level, biliary excretion and clinical efficacy.
    The serum peak level of BIPM was 12.1μg/ml reached in 0.5 hours after the administration of 300mg by intravenous drip, and the serum half-time was 1.02 hours.
    The peak concentration in bile was 8.10μg/ml in 1.5 hours after the administration.
    Clinical response was good in all nine cases treated with this drug, and all 17 bacterial strains isolated from eight out of the nine cases as causative bacilli were eradicated after treatment. No side effects were noted, however slight mild elevation of serum GOT in one case was recognized.
    View full abstract
    Download PDF (651K)
  • Clinical study on biapenem in surgical infections
    Akio Hizuta, Akira Gohchi, Hiromi Iwagaki, Kunzou Orita, Hideyuki Kimu ...
    1994 Volume 42 Issue Supplement4 Pages 843-847
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_843
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A clinical study on biapenem (BIPM), a new carbapenem was performed in 13 infected patients in the field of surgery. There were obtained excellent in 5 patients, good in 6 and fair in 2, that is, the clinical efficacy rate was 84.6%.
    Bacteriological efficacy rate was 100%.
    No adverse reaction was noted, though the mild and transient disorder in liver function, increase of platelet and eosinophiles counts were observed in one case respectively.
    From the above results, BIPM was considered both the useful and safe antibiotic.
    View full abstract
    Download PDF (525K)
  • Clinical Studies on biapenem in Obstetrics and Gynecology
    Tetsuro Chimura, Toshio Hirayama, Noriyasu Saitou, Nobuyuki Morisaki
    1994 Volume 42 Issue Supplement4 Pages 848-851
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_848
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Biapenem (BIPM), a newly developed injectable carbapenem antibiotic, was studied to determine its usefulness in the fields of obstetrics and gynecology. The results of the study were as follows:
    1) The subjects consisted 14 patients with intrauterine infection (n=7), adnexal infection (n=4), intrapelvic infection (n=3). Evaluating clinical efficacy, BIPM was administered drip infusion of 0.6-1.2g/day for 3 to 7 days (total doses of 1.5 to 6.0g).
    2) Clinically, one case (salpingitis) was judged as excellent, 13 (intrauterine infection and other) as good, resulting in a total effective rate of 100%. Bacteriological effectiveness corresponded to 7/7 (100%).
    3) Neither subjective nor objective side effects were observed, except for one case with increased level of eosinophilie.
    These results suggest that BIPM appears to be useful against obstetrics and gynecological infections.
    View full abstract
    Download PDF (444K)
  • Clinical efficacy of biapenem in obstetric and gynecological infections
    Hiroshi Endo, Ko Asano, Katsuyuki Takahashi, Risa Takaya, Michihiro Yu ...
    1994 Volume 42 Issue Supplement4 Pages 852-856
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_852
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We performed clinical studies on biapenem (BIPM), a new injectable carbapenem antibiotics for its clinical efficacy in obestetric and gynecological infections. A daily dose of 600-1, 200mg of BIPM was administered intravenouslly for 3-10 days.
    BIPM was administered to 12 patients with endometritis (3), puerperal uterine infection (2), pyometra (2), salpigitis (2), oophoritis (1), Douglas abscess (1) and Bartholin's abscess (1). The following results were obtained.
    1. The clinical effect was good in 12 cases, and the efficacy rate was 100%.
    2. Bacteriologically, 13 strains were isolated from 9 patients. The causative organisms were eliminated in 10 strains and the eradication rate was 76.9%.
    3. No side effect were observed in any cases. A transient elevation of GPT and Al-P occurred in one patient. BIPM is expected to be useful in the treatment of obestetric and gynecological infections.
    View full abstract
    Download PDF (620K)
  • Clinical study of biapenem in patient with gynecologic infections
    Ken Takizawa, Tomiko Iguchi, Yoshihiko Takeda
    1994 Volume 42 Issue Supplement4 Pages 857-859
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_857
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Biapenem (BIPM) is a new 4-methyl carbapenem antibiotic with an exceptionally broad spectrum of an antibacterial activity in vitro and is stable to human renal dehydropeptidase -I (DHP-I). In this study, BIPM was intravenouslly administered to 4 patients with acute salpingitis at a dose of 300mg, 2 times for 4 to 6 consecutive days.
    The clinical effects of BIPM were estimated to be excellent in 2 cases and good in 2 cases as for bacterial effect, three strains, Corynebacterium sp., Prevotella bivia and Bacteroides melaninogenicus, were eradicated after treatment. No side effects or abnormal laboratory test values were observed. Ultimately, BIPM were very useful for gynecologic infections.
    View full abstract
    Download PDF (468K)
  • Clinical evaluation of biapenem for gynecological infections
    Keiichi Sakakura, Yoshiyuki Iwata
    1994 Volume 42 Issue Supplement4 Pages 860-862
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_860
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Biapenem (BIPM), a new carbapenem antibiotic, was administered to 6 patients with gynecological infections at a unit dose of 300mg, two times a day, for 7 or 7.5 days.
    The following results were obtained.
    1) BIPM was effective in all 6 case, including 1 of postpuerperal intrauterine infection, 1 of salpingitis, 1 of ovarian abscess, 3 of pelvic peritonitis.
    2) Evaluation of bacteriological efficacy: Bacteria were detected in 3 cases and they were eliminated in all cases.
    3) Neither side effects nor abnormal laboratory findings responsible for this drug were observed.
    View full abstract
    Download PDF (359K)
  • Clinical studies on biapenem in obstetrics and gynecology
    Yoshiaki Yagami, Seiji Hanada, Katsuo Ikuta, Satoru Hori, Nobuyuki Hos ...
    1994 Volume 42 Issue Supplement4 Pages 863-866
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_863
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The clinical effects and safety of biapenem (BIPM) on infectious diseases in the field of obstetrics and gynecology were investigated in 11 patients.
    The drug was intravenously infused at a dose of 300mg twice a day. The effect was excellent in 5, good in 5. We noted no adverse reactions or abnormalities of laboratory findings.
    View full abstract
    Download PDF (533K)
  • Clinical studies on biapenem in the obstetrical and gynecological infection
    Osamu Ishiko, Yuji Fujino, Motoharu Imanaka, Hiroyuki Onaka, Kenichi H ...
    1994 Volume 42 Issue Supplement4 Pages 867-871
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_867
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Clinical studies on biapenem (BIPM), a new carbapenem antibiotic, were performed and the following results were obtained.
    BIPM was administered to 8 cases with obstetric and gynecological infections such as puerperal intrauterine infection, pyometra, endometritis, salpingitis, pelveoperitonitis, bartholinitis and bacterial vaginitis.
    The efficacy was evaluated as good in 5 cases and unknown in 2 cases. As the efficacy rate of BIPM was 83.3%.
    No side effects and abnormal laboratory findings were observed during the treatment in all patients.
    View full abstract
    Download PDF (594K)
  • Clinical value of biapenem in obstetrics and gynecology
    Nobuyoshi Takasugi, Osamu Takeda, Hiroshi Suehiro, Masakatsu Sase, Hir ...
    1994 Volume 42 Issue Supplement4 Pages 872-878
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_872
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We performed clinical studies on biapenem (BIPM), a new carbapenem antibiotic, in obstetric and gynecological fields and obtained the following results.
    BIPM was administered to 16 patients with gynecological infection. Three cases were dropped out. In other 13 cases, the clinical results were excellent in 0 case, good in 10 cases and poor in 3 cases, showing the total effective rate of 77%.
    No critical side effects were observed at all.
    These results indicated that BIPM was a promising aid in obstetric and gynecological infections.
    View full abstract
    Download PDF (843K)
  • Clinical trial of biapenem in the dermatological field
    Shinichi Watanabe, Miyuki Kobayashi, Hiroyuki Okada, Hiroaki Abe, Miki ...
    1994 Volume 42 Issue Supplement4 Pages 879-882
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_879
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Biapenem (BIPM), a new carbapenem antibiotic, was administered to 9 patients with suppurative skin and soft tissue infection.
    Clinical efficacy and safety were evaluated. Clinical efficacy was excellent in 2 patients, good in 5, poor in 1 and unknown in 1.
    Eruption was observed as side effects in one patients. As abnormal laboratory findings, elevation of β2-microglobulin was observed in one case.
    View full abstract
    Download PDF (536K)
  • Clinical study of biapenem in otorhino otorhinolaryngology
    Hideyo Asai, Teruhisa Noiri, Toshiko Kamihata, Yusuke Watanabe, Junich ...
    1994 Volume 42 Issue Supplement4 Pages 883-888
    Published: December 28, 1994
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.42.Supplement4_883
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The effectiveness and safety of the new carbapenem antibiotic, biapenem (BIPM), for infections in the otorhinolaryngological field were evaluated. The drug was administered to 23 patients, but 1 was excluded from the study. Clinical efficacy rate 77.3% and as for bacteriological efficacy, the eradication rate was 83.3% in 22 cases. No adverse drug reaction or abnormal laboratory findings were observed in all cases. The results suggest that the drug is extremely effective and useful for bacterial infections in the otorhinolaryngological field.
    View full abstract
    Download PDF (775K)
feedback
 Top